Evolus Q2: Jeuveau Slump, Evolysse Shines, Profitability in Sight

Evolus Q2 earnings show a four percent revenue increase, but they missed their target. Jeuveau sales dropped for the first time since launch, impacted by a slumping U.S. aesthetics market. However, Evolysse fillers debuted strong, netting $9.7 million. Despite market toughness, customer surveys predict over ten percent patient volume growth in the second half. Evolus increased market share and added new accounts, while cutting non-GAAP operating expenses by $25 million. They aim for profitability in Q4 2025 and full-year positive in 2026. Jeuveaus JAMA Dermatology study data supports its superiority over competitors. Evolysses launch exceeded expectations, and Evolus plans to expand internationally. The company aims for $700 million revenue and twenty percent margins by 2028. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/03d6f1dd967526d3